Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study

Gynecologic Oncology
G P SuttonW P McGuire

Abstract

A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix. A starting dose of 1.5 g/m2 IFX iv daily for 5 days and 300 mg/m2 mesna iv every 4 hr with three doses daily after IFX were given. In patients who had received prior radiotherapy or chemotherapy, the starting dose of IFX was reduced to 1.2 g/m2. Forty-six patients were entered, and 41 are evaluable for toxicity. Forty patients are evaluable for response. Age range was 30-72 yr. GOG performance status was 0-1 for all but 2 patients. Fifteen patients (37.5%) developed GOG grade 3 or 4 granulocytopenia, and 1 developed grade 4 thrombocytopenia. One patient developed transient renal insufficiency. There was one complete response and five partial responses (12.5%) for a response rate of 15.0%. Median response duration was 4.2 months (range, 1.7-22.6 months). Three responses were seen in areas with pelvic disease only. Three responses were observed in extrapelvic sites. IFX possesses activity which compares favorably with that of other agents in this disease.

Citations

Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·C H ChoiD-S Bae
Jul 10, 2012·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Toshihiro KimuraShoji Kamiura
Sep 1, 1996·Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN·P R Klemm, C Guarnieri
Feb 1, 1995·Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN·D L Lowdermilk
Jul 29, 2008·Cancer Treatment Reviews·D PectasidesE Pectasides
Jun 6, 2008·Gynecologic Oncology·Xia TaoJohn J Kavanagh
Apr 9, 2008·Journal of Pain and Symptom Management·Rodrigo DienstmannCarlos Gil Ferreira
Jun 8, 2012·Journal of Clinical Nursing·Hilary Jefferies, Collette Clifford
Jan 26, 2010·American Journal of Obstetrics and Gynecology·Robert T GreenleeDouglas J Reding
Nov 1, 1996·American Journal of Obstetrics and Gynecology·J A ChapmanM L Berman
Jul 14, 1998·American Journal of Obstetrics and Gynecology·D E CohnB A Goff
Sep 1, 1996·American Journal of Obstetrics and Gynecology·G S RoseJ C Hiserodt
Dec 1, 1996·American Journal of Obstetrics and Gynecology·P C Morris, V Scholten
Dec 22, 1999·Gynecologic Oncology·J P GeislerW Crabtree
Sep 7, 2007·Gynecologic Oncology·Isabelle CadronIgnace Vergote
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David Scott MillerRobert S Mannel
Jul 6, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Perry W GrigsbyGiuseppe Del Priore
Sep 26, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K Y LookUNKNOWN Gynecologic Oncology Group Study
Jun 11, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Dimitrios PectasidesTheofanis Economopoulos
Dec 5, 2013·Anti-cancer Drugs·Carlton L SchwabAlessandro D Santin
Jan 17, 2014·Expert Review of Anticancer Therapy·Laurie M Elit, Hal Hirte
Jan 1, 2010·Oncology Letters·Angiolo GadducciLuca Cionini
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P CurtinR D Alvarez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.